Schmidt Dörthe, Hoerstrup Simon P
Division of Regenerative Medicine (Tissue Engineering and Cell Transplantation), Department of Surgical Research and Clinic for Cardiovascular Surgery, University Hospital, Zurich, Switzerland.
Swiss Med Wkly. 2007 Mar 2;137 Suppl 155:80S-85S.
Valvular heart disease is still a significant cause of morbidity and mortality worldwide. Clinically used valve replacements including mechanical valves as well as fixed biological xeno- or homografts are associated with several major disadvantages. Alternatively, tissue engineering aims at the fabrication of autologous living cardiovascular replacements with the potential to grow and to repair, particularly for paediatric applications. Therefore, autologous cells are harvested and seeded onto three-dimensional matrices followed by biomimetic in vitro conditioning enabling the development of the neo-heart valve tissue. Here, we review different human cell sources such as vessels, bone marrow, umbilical cord tissue and blood, and chorionic villi with particular regard to cell phenotypes and their suitability for extracellular matrix production for tissue engineering purposes.
心脏瓣膜疾病仍是全球发病和死亡的重要原因。临床上使用的瓣膜置换物，包括机械瓣膜以及固定的生物异种或同种移植物，都存在几个主要缺点。相比之下，组织工程旨在制造具有生长和修复潜力的自体活心血管替代物，特别是用于儿科应用。因此，采集自体细胞并接种到三维基质上，然后进行仿生体外培养，以促进新心脏瓣膜组织的发育。在此，我们综述了不同的人类细胞来源，如血管、骨髓、脐带组织和血液以及绒毛膜绒毛，特别关注细胞表型及其在组织工程中用于细胞外基质生产的适用性。
